拜玛林制药 BMRN 深 沪
等待开盘 02-03 09:30:00 美东时间
57.95
+1.410
+2.49%
华盛通- 最 高58.50
- 今 开56.395
- 成交量 186.34万股
- 最 低 56.255
- 昨 收 56.54
- 总市值 111.26亿
- 52周最高 73.51
- 市盈率 静 26.25
- 换手率 0.97%
- 52周最低 50.76
- 委 比 -94.19%
- 总股本 1.92亿
- 历史最高 151.75
- 量 比 1.06
- 振 幅 3.97%
- 历史最低 23.735
- 每 手 1
- 风险率 5.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Reported Earlier: BioMarin Launches $2B Term Loan B Financing To Fund Pending Amicus Therapeutics Acquisition
BioMarin also announced that, in connection with the pending acquisition (the "Acquisition") of Amicus Therapeutics, Inc. ("Amicus"), it launched the syndication of a new $2 billion senior secured term loan "B" facility
01-26 21:49
财报速睇 | 拜玛林制药 2025财年Q3营收4.49亿美元；归母净利润亏损0.29亿美元
华盛资讯1月26日讯，拜玛林制药公布2025财年Q3业绩，公司Q3营收4.49亿美元，，归母净利润亏损0.29亿美元，。
01-26 21:17
BioMarin to Acquire Amicus Therapeutics in Proposed Deal
BioMarin to Acquire Amicus Therapeutics in Proposed Deal BioMarin Pharmaceutical Inc. is moving forward with its previously announced plan to acquire Amicus Therapeutics, Inc. In an update, Amicus disclosed that as of December 31, 2025, it had approximately $294 million in cash, cash equivalents, an
01-26 21:12
BioMarin Pharmaceutical Plans To Offer $850M Senior Notes Due 2034 Offering
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured notes due 2034 (the "Notes").
01-26 20:47
BioMarin Pharmaceutical Launches $3.65 Billion Debt Offering for Amicus Acquisition
BioMarin Pharmaceutical Launches $3.65 Billion Debt Offering for Amicus Acquisition BioMarin Pharmaceutical Inc. has announced its intention to offer, subject to market and other conditions, $850 million of senior unsecured notes due 2034. The proceeds from this debt issuance, along with borrowings
01-26 20:45
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
Canaccord Genuity Upgrades BioMarin Pharmaceutical to Buy, Raises Price Target to $98
Canaccord Genuity analyst Whitney Ijem upgrades BioMarin Pharmaceutical (NASDAQ:BMRN) from Hold to Buy and raises the price target from $84 to $98.
01-20 20:57
BioMarin Appoints Arpit Davé Chief Digital and Information Officer
Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical ...
01-13 05:05
不再迷惘的制药商：2025年并购额暴涨124%，巨头狂扫创新药资产
那些关于药品定价政策及可能侵蚀利润的关税措施的最坏担忧均未成真，行业焦虑情绪得到明显缓解。 智通财经APP获悉，下周，制药商们将赴旧金山出席摩根大通医疗健康年...
01-10 00:49
不再迷惘的制药商：2025年并购额暴涨124%，巨头狂扫创新药资产
下周，制药商们将赴旧金山出席摩根大通医疗健康年会，心态较2025年显著放松。回溯一年前，他们还对美国总统唐纳德·特朗普的政策走向感到困惑迷惘;如今，此前笼罩的诸...
01-09 21:50
